Background: T H 2 cells and their cytokines are associated with allergic asthma in human subjects and with mouse models of allergic airway disease. IL-4 signaling through the IL-4 receptor a (IL-4Ra) chain on CD4 1 T cells leads to T H 2 cell differentiation in vitro, implying that IL-4Ra-responsive CD4 1 T cells are critical for the induction of allergic asthma. However, mechanisms regulating acute and chronic allergen-specific T H 2 responses in vivo remain incompletely understood. Objective: This study defines the requirements for IL-4Raresponsive CD4 1 T cells and the IL-4Ra ligands IL-4 and IL-13 in the development of allergen-specific T H 2 responses during the onset and chronic phase of experimental allergic airway disease. Methods: Development of acute and chronic ovalbumin (OVA)-induced allergic asthma was assessed weekly in CD4 1 T cell-specific IL-4Ra-deficient BALB/c mice (Lck cre IL-4Ra 2/lox ) and respective control mice in the presence or absence of IL-4 or IL-13. Results: During acute allergic airway disease, IL-4 deficiency did not prevent the onset of T H 2 immune responses and OVAinduced airway hyperresponsiveness or goblet cell hyperplasia, irrespective of the presence or absence of IL-4Ra-responsive CD4 1 T cells. In contrast, deficiency of IL-13 prevented allergic asthma, irrespective of the presence or absence of IL-4Raresponsive CD4 1 T cells. Importantly, chronic allergic inflammation and airway hyperresponsiveness were dependent on IL-4Ra-responsive CD4 1 T cells. Deficiency in IL-4Raresponsive CD4 1 T cells resulted in increased numbers of IL-17-producing T cells and, consequently, increased airway neutrophilia. Conclusion: IL-4-responsive T helper cells are dispensable for acute OVA-induced airway disease but crucial in maintaining chronic asthmatic pathology. (J Allergy Clin Immunol 2016;137:1852-62.) 
Allergic asthma is a chronic inflammatory disease of the airways characterized by an inappropriate immune response to harmless environmental antigens. T H 2 cells regulate adaptive immune responses to allergens, and their presence correlates with disease symptoms in human subjects and mice. 1 IL-4 plays a crucial role in the in vitro and in vivo differentiation of T H 2 cells, suggesting major contributions for IL-4 and its receptor, IL-4 receptor a (IL-4Ra), in regulating allergic T H 2 responses. 2 However, the initiation and maintenance of in vivo T H 2 differentiation is incompletely understood. The IL-4/IL-4Ra pathway is not essential for T H 2 polarization in certain in vivo settings, and important roles for the cytokines IL-25 and IL-33 and type 2 innate lymphoid cells (ILC2s) have been suggested. 2 Several studies described IL-4-independent T H 2 differentiation in response to allergens or helminth infection. 3, 4 Other studies suggested that IL-4 signaling is required for the expansion and maintenance of T H 2 responses after Nippostrongylus brasiliensis infection or allergen treatment but not for the initial T H 2 differentiation. 5, 6 Although we and others have described IL-4Ra-independent airway hyperresponsiveness (AHR), 7, 8 mouse models of allergic asthma generally highlight the importance of IL-4, IL-5, IL-13, and the IL-4Ra/signal transducer and activator of transcription 6 signaling pathway for the development of allergic pathology, including airway eosinophilia, goblet cell hyperplasia, and AHR. Mice deficient in IL-4Ra showed abrogated T H 2 cell differentiation and were protected from ovalbumin (OVA)-induced allergic airway disease. [9] [10] [11] IL-4Ra is ubiquitously expressed, and we and others have successfully used mice with cell type-specific disruptions of the Il4ra gene to identify IL-4Ra-dependent disease symptoms mediated by airway epithelial cells, 12 smooth muscle cells, 11, 13 and macrophages. 10 The in vivo requirements for IL-4Ra signaling on CD4 1 T cells in the initiation of allergen-specific T H 2 responses remain incompletely understood. Furthermore, it has been shown that CD4 1 cells and IL-4 are required for chronic lung inflammation and AHR but might not be necessary for chronic pathogenesis, including AHR, after acute inflammatory responses have resolved. [14] [15] [16] [17] In the present study we used previously described Lck cre IL-4Ra 2/lox mice with a CD4 1 T cell-specific IL-4Ra disruption 18 to define whether IL-4Ra-responsive CD4 1 T cells and the IL-4Ra ligands IL-4 and IL-13 are required for the initial in vivo differentiation of an allergen-specific T H 2 response and the subsequent onset of OVA-induced allergic airway disease. Furthermore, we investigated whether CD4 1 T cells require IL-4Ra signals to sustain a T H 2-type phenotype and to promote disease pathology during chronic allergic airway inflammation. We found that acute allergic airway disease and T H 2 differentiation are independent of IL-4 signaling and that IL-13 drives airway pathology. Loss of IL-4Ra signaling on CD4 1 T cells resulted in increased IL-17 production and airway neutrophilia. Importantly, IL-4-responsive CD4 1 T cells promoted chronic asthmatic disease. In conclusion, IL-4-responsive T helper cells are dispensable for acute OVA-induced airway disease but required to maintain chronic asthmatic pathology.
METHODS Mice
Six-to 8-week-old female mice were used in the experiments. Generation of Lck cre IL-4Ra 2/lox (C.Cg-Il4ra tm1Fbb /Il4ra tm2Fbb-Tg[Lck-Cre]/J ) mice and IL-4R 2/lox littermates on a BALB/c background was described previously. 18 Lck cre IL-4Ra 2/ lox mice and IL-4Ra 2/lox littermate control mice were intercrossed with IL-4deficient 19 or IL-13-deficient 20 BALB/c mice for 9 generations. Animal procedures were approved by the University of Cape Town Animal Ethics Committee.
Models of allergic airway disease
Acute OVA-induced allergic airway disease. Mice were sensitized intraperitoneally and challenged intranasally with OVA (Sigma-Aldrich, Aston Manor, South Africa), as previously described. 10 In some experiments mice received 0.2 mg/mouse anti-IL-17A antibody 21 (clone MM17F3, kind gift of C. Uyttenhove) or isotype-matched control antibody by means of intraperitoneal injection on days 20 and 23.
Chronic OVA-induced allergic airway disease. Mice were sensitized subcutaneously with 20 mg of OVA adsorbed to 0.65% alum on days 0, 7, 14, and 21. On days 27 and 29 and then twice weekly for 4 weeks, mice were challenged intranasally with 20 mg of OVA in 50 mL of PBS after achievement of anesthesia. 10 
AHR
Respiratory resistance and compliance of the whole respiratory system and Newtonian resistance of the central airways were determined by means of forced oscillation measurements with a flexiVent system (SCIREQ, Montreal, Quebec, Canada) by using the single-compartment (''snapshot'') perturbation or constant phase model, as previously described. 11
Evaluation of goblet cell hyperplasia
Periodic acid-Schiff reagent-positive goblet cells and total epithelial cell nuclei in 5 to 8 bronchioles per lung section containing 80 to 220 epithelial cells were counted, and the ratio was converted to a percentage. 13 
Measurement of serum antibody levels
Total IgE and allergen-specific IgG antibody levels were measured by means of ELISA, as described previously. 11 
Analysis of airway and lung cell populations
Single-cell suspensions were prepared from lungs of individual mice and stained for intracellular cytokines, as previously described. 10 Bronchoalveolar lavage (BAL) 11 and lung cell composition of individual mice was determined by means of cell-surface staining with Siglec-F-phycoerythrin (PE), CD11c-allophycocyanin, and GR-1-fluorescein isothiocyanate (FITC) for eosinophils, neutrophils, and alveolar macrophages; CD3-PE, CD4peridinin-chlorophyll-protein complex, and T1/ST2-FITC for T helper cells; and lineage-peridinin-chlorophyll-protein complex-Cy5.5, inducible costimulator (ICOS)-allophycocyanin, and T1/ST2-FITC for ILC2s. Flow cytometry was performed on a FACSCalibur flow cytometer (BD Biosciences, Erembodegem, Belgium), and data were analyzed with FlowJo version 10 software (TreeStar, Ashland, Ore). All antibodies were purchased from BD Biosciences or eBioscience (San Diego, Calif), except T1/ST2 (MD Bioproducts, St Paul, Minn). In some experiments BAL cells were stained with the Rapi-Diff Stain Set (Clinical Diagnostics CC, Johannesburg, South Africa) and analyzed based on differential cell counts, as described previously. 11 
Analysis of lung cytokine responses
Cytokine concentrations in lung tissue homogenate (1 mg/mL protein concentration) were determined by means of ELISA, according to the manufacturer's protocols (IL-4, IL-5, and IFN-g: BD Biosciences; IL-13, IL-17, IL-25, and IL-33: R&D Systems, Minneapolis, Minn). 
Statistical analysis

RESULTS
Development of OVA-induced allergic airway disease in Lck cre IL-4Ra 2/lox mice
The role of IL-4Ra-responsive CD4 1 T cells in acute OVAinduced allergic airway disease was investigated by using CD4 1 T cell-specific IL-4Ra-deficient mice (Lck cre IL-4Ra 2/lox ) and IL-4Ra-responsive IL-4Ra 2/lox littermate control mice (Fig 1, A) . IL-4Ra was efficiently disrupted on the cell surfaces of CD3 1 CD4 1 T cells but present on CD3 1 CD8 1 T cells from lungs of OVA-treated Lck cre IL-4Ra 2/lox mice, confirming previous results (see Fig E1, A, in this article's Online Repository at www.jacionline.org). 18 Development of AHR, airway eosinophilia, and goblet cell hyperplasia are the main characteristics of allergic airway disease and were absent in saline-treated Lck cre IL-4Ra 2/lox mice and IL-4Ra 2/lox littermate control animals (see Fig E1, B-D). In OVA-treated mice respiratory resistance and compliance of the whole respiratory system and Newtonian resistance of the central airways were measured in response to increasing doses of inhaled methacholine as indicators of AHR. Importantly, AHR was not affected by the loss of IL-4Ra expression on CD4 1 T cells. OVA treatment induced increased respiratory and Newtonian resistance and a decrease in respiratory compliance in CD4 1 T cell-specific IL-4Ra-deficient mice (Lck cre IL-4Ra 2/lox ) and IL-4Ra-expressing IL-4Ra 2/lox littermate control mice, with no significant differences between these groups (Fig 1, B) . Furthermore, efficient goblet cell hyperplasia was observed after OVA treatment in Lck cre IL-4Ra 2/lox mice and littermate control mice but not in PBS-treated control animals, with no significant differences between the OVA-treated groups (Fig 1, C) .
A model of subcutaneous sensitization was then used to investigate whether the route of sensitization affected our results. 10 Subcutaneous sensitization led to comparable pathology with intraperitoneal sensitization in Lck cre IL-4Ra 2/lox mice and IL-4Ra 2/lox littermate control mice with regard to AHR and goblet cell hyperplasia, confirming that these parameters were not dependent on the route of sensitization (see Fig E2 in this article's Online Repository at www. jacionline.org). Allergic airway inflammation is characterized by infiltration of the lungs by eosinophils. OVA treatment led to significant cell infiltration in the BAL, and the total number of cells was not affected by the loss of CD4 1 T-cell IL-4Ra ( Fig  1, D) . OVA-treated CD4 1 T cell-specific IL-4Ra-deficient mice (Lck cre IL-4Ra 2/lox ) and IL-4Ra-expressing IL-4Ra 2/lox littermate control mice showed increased numbers of eosinophils, neutrophils, and CD3 1 CD4 1 T helper cells but not alveolar macrophages in the BAL fluid (Fig 1, E) and lung tissue (see Fig E3, A, in this article's Online Repository at www.jacionline. org). However, the number of eosinophils was reduced in Lck cre IL-4Ra 2/lox mice compared with littermate control animals, whereas the number of neutrophils was significantly higher in the BAL fluid (Fig 1, E) . Although eosinophil numbers were increased compared with neutrophil numbers in IL-4Ra 2/lox littermate control mice, eosinophil and neutrophil numbers were similar in Lck cre IL-4Ra 2/lox mice. BAL and lung tissue eosinophils in OVA-treated Lck cre IL-4Ra 2/lox mice and littermate control animals showed similar upregulation of Siglec-F surface expression, indicating an activated phenotype in both strains (Fig 1, F , and see Fig E3, B ). 22, 23 Together, these results demonstrate that IL-4Ra expression on CD4 1 T cells is not necessary for the development of major symptoms of allergic airway disease in mouse models of systemic OVA/alum sensitization.
Lck cre IL-4Ra 2/lox mice maintain T H 2-type cytokine responses to OVA Because the development of allergic airway disease is regulated by T H 2-associated cytokines, we examined the effect of a lack of IL-4Ra responsiveness by lung CD4 1 T cells on their cytokine production. OVA treatment increased numbers of CD4 1 T cells producing the T H 2 cytokines IL-4, IL-5, and IL-13 in OVAtreated Lck cre IL-4Ra 2/lox mice and littermate control mice, with no significant differences between these groups (Fig 2, A) . These results suggest that IL-4Ra signaling on CD4 1 T cells is not required for the in vivo differentiation of IL-4-, IL-5-, and IL-13-producing T H 2 cells. Treatment with OVA also promoted a strong IFN-g response from CD4 1 T cells in both Lck cre IL-4Ra 2/lox mice and littermate control mice. IL-17producing CD4 1 T cells were significantly upregulated in Lck cre IL-4Ra 2/lox mice compared with IL-4Ra 2/lox mice, indicating that IL-4Ra signaling on CD4 1 T cells inhibits the development of T H 17 responses (Fig 2, A) . Analysis of lung tissue cytokines and cytokine secretion of ex vivo-stimulated lung cells by means of ELISA confirmed a T H 2-type cytokine profile in Lck cre IL-4Ra 2/lox mice and IL-4Ra 2/lox mice, whereas IL-17 concentrations were increased only in Lck cre IL-4Ra 2/lox mice (see Fig E4 in this article's Online Repository at www. jacionline.org). The cytokines IL-25 and IL-33 have been implicated in the development of type 2 immune responses in allergic diseases. 2 We found no significant increase in IL-25 concentrations in lung tissue homogenates after OVA treatment. However, IL-33 concentrations were upregulated in IL-4Ra 2/lox and Lck cre IL-4Ra 2/lox mice after OVA treatment (Fig 2, B) . IL-33 signals through the T1/ST2 receptor, which is primarily expressed on T H 2 cells but not on other T-cell subtypes. 24 In agreement with the T H 2 cytokine profile in T cells, we found similar numbers of T1/ ST2-expressing CD3 1 CD4 1 T cells in the lungs of IL-4Ra 2/lox and Lck cre IL-4Ra 2/lox mice (Fig 2, C) . In addition to its role in T H 2 cell functions, IL-33 has been implicated in the differentiation of ILC2s, which are able to promote type 2 immune responses and have been linked to allergic airway inflammation. 25 Allergen challenge increased numbers of a lineage-negative ICOS 1 T1/ ST2 1 ILC2 population in the lungs of IL-4Ra 2/lox and Lck cre IL-4Ra 2/lox mice (Fig 2, D) , which had an activated phenotype, as indicated by increased ICOS surface expression (Fig 2,  E) . 26 In conclusion, the main features of the adaptive and innate type 2 immune response were maintained in the absence of IL-4Ra on T cells, whereas T H 17 responses were increased.
Reduced IgE responses to OVA in Lck cre IL-4Ra 2/lox mice T H 2-type immune responses are associated with antibody isotype switching to IgE and IgG 1 , whereas IFN-g promotes 8) . B, IL-25 and IL-33 levels were measured in lung tissue homogenate by using ELISA (n 5 9, 12, and 12). C and D, IL-33 receptor (ST2) expressing CD3 1 CD4 1 T cells (Fig 2, C) and lineage 2 ICOS 1 ST2 1 ILC2 populations (Fig 2, D) were detected with fluorescence-activated cell sorting (n 5 9, 12, and 12). E, Mean fluorescence intensity (MFI) of ICOS-PE staining on lung ILC2s. Data were pooled from 2 independent experiments. F, Total IgE and OVA-specific IgE levels in blood serum were measured by means of ELISA. Data were pooled from 3 independent experiments. (n 5 10). Lines represent medians 6 interquartile ranges. *P < .05, **P < .01, and ***P < .001, Kruskal-Wallis nonparametric test.
IgG 2a and IgG 2b responses. In Lck cre IL-4Ra 2/lox mice total and OVA-specific IgE serum concentrations were significantly reduced compared with those in littermate control mice (Fig 2,  F) . IgG responses were similar in CD4 1 T cell-specific IL-4Ra-deficient mice (Lck cre IL-4Ra 2/lox ) and littermate control mice, with high OVA-specific IgG 1 and low IgG 2a and IgG 2b titers (see Fig E5 in this article's Online Repository at www.jacionline.org).
IL-13, but not IL-4, is required for development of OVA-mediated allergic airway disease
To clarify whether disease development in CD4 1 T cellspecific IL-4Ra-deficient mice (Lck cre IL-4Ra 2/lox ) requires IL-4 or IL-13, we examined allergic airway responses in these mice in the presence (Lck cre IL-4Ra 2/lox ) or absence of IL-4 (IL-4 2/2 Lck cre IL-4Ra 2/lox ) or IL-13 (IL-13 2/2 Lck cre IL-4Ra 2/ lox ). IL-4 was not needed for OVA-induced AHR (Fig 3, A) because IL-4-deficient mice in the presence or absence of IL-4Ra-expressing CD4 1 T cells (IL-4 2/2 IL-4Ra 2/lox mice or IL-4 2/2 Lck cre IL-4Ra 2/lox ) showed similar AHR responses compared with IL-4-competent littermate control animals (IL-4Ra 2/lox mice). In stark contrast, IL-13 was crucial for OVA-induced AHR (Fig 3, A) because IL-13-deficient mice in the presence (IL-13 2/2 IL-4Ra 2/lox ) or absence (IL-13 2/ 2 Lck cre IL-4Ra 2/lox ) of IL-4Ra-expressing CD4 1 T cells did not have AHR compared with IL-13-competent littermate controls (IL-4Ra 2/lox ). The absence of IL-4 and IL-4Ra-responsive CD4 1 T cells did not significantly change the percentage of goblet cells in the airway epithelium, whereas goblet cell hyperplasia was impaired in the absence of IL-13 (Fig 3, B) . IL-4 and IL-13 were required for the development of allergic airway inflammation because IL-4 or IL-13 deficiency in Lck cre IL-4Ra 2/lox mice and IL-4Ra-expressing littermate control mice reduced eosinophilia and increased neutrophilia in the BALF (Fig 3, C) . Lymphocyte and macrophage numbers were increased in all treatment groups compared with PBS-treated control mice, with no significant differences between the groups (Fig 3, D) . As expected from IL-4 being responsible for isotype class-switching to IgE, serum concentrations of IgE were drastically reduced in OVA-challenged IL-4-deficient mouse strains (IL-4 2/2 IL-4Ra 2/ lox and IL-4 2/2 Lck cre IL-4Ra 2/lox mice) compared with those in IL-4Ra 2/lox control mice (Fig 3, E) . Because murine B cells are unresponsive to IL-13, mice deficient in IL-13 (Fig 3, D) and OVA-specific IgG 1 (Fig 3, E) in blood serum were measured by means of ELISA (n 5 8). Data were pooled from 2 independent experiments. Lines represent means 6 SEMs. *P < .05, **P < .01, and ***P < .001 versus PBS control. #P < .05 and ###P < .001 versus IL-4Ra 2/lox . Fig 3, A, Two-way repeated-measures ANOVA at 40 mg/mL methacholine. (IL-13 2/2 IL4Ra 2/lox ) responded similarly to OVA challenge compared with IL-4Ra 2/lox control mice. However, in mice with IL-13 deficiency and IL-4Ra-unresponsive CD4 1 T cells (IL-13 2/2 Lck cre IL-4Ra 2/lox mice), IgE concentrations were strikingly reduced. This was expected because CD4 1 T cell-4Ra expression is required for a normal IgE response (Fig 2,  F) . 27 OVA-specific IgG 1 concentrations were similar in IL-4Ra 2/lox , Lck cre IL-4Ra 2/lox , IL-13 2/2 IL-4Ra 2/lox , and IL-13 2/2 Lck cre IL-4Ra 2/lox mice but reduced in mice with an IL-4-deficient genetic background.
In summary, the data presented here show that acute OVA-mediated allergic airway disease and a T H 2-polarized immune response can develop independently of IL-4 and IL-4Ra expression on CD4 1 T cells. Furthermore, these results show that IL-13, but not IL-4, is mainly responsible for an allergic phenotype.
IL-17 induces neutrophilic airway inflammation in
Lck cre IL-4Ra 2/lox mice OVA exposure induced a significant increase in neutrophil counts in BAL fluid (Fig 1, E) and in IL-17 1 CD4 1 T cells and IL-17 in the lungs (Fig 2, A, and see Fig E4) of Lck cre IL-4Ra 2/lox mice but not littermate control mice. IL-17 can orchestrate neutrophil infiltration in mouse models of allergic asthma and has been associated with the development of severe asthma and AHR. 28, 29 Anti-IL-17 antibodies injected during intranasal OVA challenge significantly reduced neutrophil numbers in Lck cre IL-4Ra 2/lox mice and IL-4Ra 2/lox littermate control mice. Eosinophil numbers were not affected by anti-IL-17 antibody treatment (Fig 4, A) . Furthermore, pulmonary resistance and compliance in Lck cre IL-4Ra 2/lox and IL-4Ra 2/lox mice were not significantly altered by anti-IL-17 treatment (Fig 4,  B) . Therefore increased production of IL-17 after disrupted IL-4Ra expression on CD4 1 T cells was responsible for airway neutrophilia but did not contribute to the development of AHR.
IL-4Ra-responsive CD4 1 T cells are required to sustain chronic AHR and eosinophilic lung inflammation
Having defined the roles of IL-4-, IL-13-, and IL-4Raresponsive CD4 1 T cells in the onset of OVA-mediated allergic asthma, we investigated the role of IL-4Ra-responsive CD4 1 T cells in maintaining chronic allergic airway disease. Mice received systemic OVA sensitization followed by intranasal challenges over 5 consecutive weeks (Fig 5, A) . 10 Baseline values for respiratory resistance and compliance measured before methacholine challenge were not affected in Lck cre IL-4Ra 2/lox and IL-4Ra 2/lox mice after 5 weeks of chronic airway exposure to allergens, indicating that chronic OVA exposure did not affect general lung function (see Fig E6, A, in this article's Online Repository at www.jacionline.org). AHR in response to methacholine did not significantly change during the 5-week course of allergen challenge in OVA-treated IL-4Ra 2/lox mice (Fig 5, B , and see Fig E7 in this article's Online Repository at www.jacionline.org). However, AHR was significantly reduced in Lck cre IL-4Ra 2/lox mice from day 45 onward and decreased to levels similar to those in PBS-treated control groups by day 52 (Fig 5, B , and see Fig E7) . Chronic airway inflammation was assessed by measuring numbers of BAL cells. BAL fluid eosinophil numbers continuously decreased over the 5-week period of allergen exposure in Lck cre IL-4Ra 2/lox and IL-4Ra 2/lox mice (Fig 5, C) . However, in CD4 1 T cell-specific IL-4Ra-deficient Lck cre IL-4Ra 2/lox mice, airway eosinophilia was significantly reduced at every time point compared with that in littermate control mice and was resolved by day 52 (Fig 5, C) . Surface expression of the activation marker Siglec-F on eosinophils was not significantly different in Lck cre IL-4Ra 2/lox and IL-4Ra 2/lox mice until day 59, when eosinophils were hard to detect in Lck cre IL-4Ra 2/lox mice (see Fig E6, B) . Airway neutrophilia was significantly increased in Lck cre IL-4Ra 2/lox mice compared with that in IL-4Ra 2/lox mice after the first week of allergen challenge, and similar numbers were observed afterward in Lck cre IL-4Ra 2/lox mice and IL-4Ra 2/lox littermate control mice (Fig 5, C) . Numbers of alveolar macrophages did not differ between Lck cre IL-4Ra 2/lox mice and IL-4Ra 2/lox littermate control mice or change significantly over the course of allergen challenge (see Fig E6, C) . Together, these results demonstrate that IL-4Ra expression on T cells is critical for maintaining the hallmarks of allergic airway disease, such as AHR and airway inflammation, in response to chronic allergen exposure.
Type 2-specific cytokine responses are maintained after impairment of IL-4Ra responsiveness in CD4 1 T cells during chronic allergic asthma OVA treatment induced T H 2 cytokine production by CD4 1 T cells from lungs independently of IL-4Ra responsiveness during chronic allergen challenge (Fig 6, A) . Numbers of CD4 1 T cells producing the T H 2 cytokines IL-4, IL-5, and IL-13 were not significantly different in CD4 1 T cell-specific IL-4Ra-deficient Lck cre IL-4Ra 2/lox mice and IL-4Ra-expressing IL-4Ra 2/lox littermate control mice throughout the course of OVA challenges. Numbers of IFN-g-or IL-10-producing CD4 1 T cells were similar in control IL-4Ra 2/lox mice and Lck cre IL-4Ra 2/lox mice. Of note, the numbers of IL-17-producing CD4 1 T cells were higher in Lck cre IL-4Ra 2/lox mice throughout the course of allergen challenge (Fig 6, A) . Total IgE and OVA-specific IgE serum concentrations were increased in IL-4Ra 2/lox compared with Lck cre IL-4Ra 2/lox mice and peaked on day 45 (Fig 6, B) . OVA-specific IgG 1 antibodies were detected at the highest concentrations on day 45, with no significant differences between IL-4Ra 2/lox and Lck cre IL-4Ra 2/lox mice (see Fig E8 in this article's Online Repository at www.jacionline.org). Levels of the type 1-associated antibodies IgG 2a and IgG 2b were increased in Lck cre IL-4Ra 2/lox mice compared with those in littermate control mice (see Fig E8) . In conclusion, impairment of IL-4Ra responsiveness by CD4 1 T cells during chronic disease leads to reduced IgE responses and enhanced T H 17 cytokine responses but does not impair T H 2 cytokine (IL-4, IL-5, and IL-13) production. 
DISCUSSION
Allergic asthma is considered to be driven by allergen-specific T H 2 immune responses, and CD4 1 T cells are an essential source of T H 2 cytokines. According to the paradigm for the development of T H 2 immunity, the IL-4/IL-4Ra signaling pathway on CD4 1 T cells is of key importance for T H 2 cell differentiation and subsequently for allergic asthma. However, mechanisms of in vivo T H 2 differentiation and the role of IL-4Ra in mouse models are not fully understood, and we and others have demonstrated that T H 2 responses can develop in the absence of the canonical IL-4/IL-4Ra-mediated pathway of T H 2 differentiation. 4, 5, [30] [31] [32] Our previous studies with CD4 1 T cell-specific IL-4Radeficient Lck cre IL-4Ra 2/lox mice in infectious disease models indicated critical contributions of IL-4Ra 1 T cells to T H 2mediated lung pathology. [33] [34] [35] However, our previous studies on mouse models of allergic dermatitis or anaphylaxis indicated that T H 2-type immune responses to allergen exposure can develop in the absence of IL-4 and IL-4Ra-expressing CD4 1 T cells. 36, 37 The present study demonstrates that IL-4-responsive T H 2 cells are crucial for chronic but not acute OVA-induced airway disease pathology and that T H 2-type immunity to OVA develops in the absence of IL-4 signaling. Furthermore, the loss of IL-4Ra signaling on CD4 1 T cells resulted in increased IL-17 production. IL-17 can orchestrate neutrophil infiltration in mouse models of allergic asthma, whereas IL-5 recruits eosinophils. Accordingly, we found similar numbers of neutrophils and eosinophils in the presence of IL-5 and IL-17 in Lck cre IL-4Ra 2/lox mice.
It is now appreciated that other cytokines, such as IL-25 and IL-33, can induce in vivo differentiation of T H 2 cells. 2 We found IL-33 and numbers of CD4 1 T cells expressing the IL-33 receptor T1/ST2 to be upregulated on airway exposure to OVA, irrespective of the presence of IL-4Ra-responsive CD4 1 T cells. IL-33 can induce production of IL-5 and IL-13 in CD4 1 T cells independently of IL-4 in vitro, 38 and IL-33-primed dendritic cells induce the development of T H 2 cells, which are crucial for allergic airway inflammation. 39 Furthermore, IL-25 and IL-33 have been associated with expansion of ILC2s in allergic responses. A recent study found that these cells drove the initiation of allergic airway inflammation in response to the protease allergen papain and mediated T H 2 responses independently of IL-4. 40 We found similar numbers of activated ILC2s in mice lacking IL-4responsive T cells and in littermate control mice, which might explain the IL-4-independent development of T H 2 responses. However, a recent study in a similar model of OVA-induced allergic asthma showed that ILC2s were dispensable in the development of T H 2 and, subsequently, the development of allergic airway inflammation responses. 41 Together with the results from our study, this indicates that systemic sensitization with OVA induces a strong T H 2-driven allergic response and ILC2 activation in the absence of the canonical IL-4-driven pathway of T H 2 differentiation.
CD4 1 T cells are required for initiation of allergic airway inflammation 42 and development of chronic asthmatic pathology in mouse models. 43 Therefore we wanted to investigate whether IL-4Ra expression by CD4 1 T cells contributes to chronic airway inflammation and disease pathology. Strikingly, disruption of IL-4Ra expression on CD4 1 T cells was sufficient to abrogate persistent AHR after 2 weeks of chronic OVA exposure. Our results and previous studies 44, 45 showed that chronic AHR did not correlate with the degree of eosinophilic airway inflammation or activation status of lung eosinophils. IL-4Ra 2/lox mice sustained AHR at a high magnitude despite a decrease in pulmonary eosinophil numbers. We found that IL-4 signaling on CD4 1 T cells contributed to the maintenance of chronic airway eosinophilia because in Lck cre IL-4Ra 2/lox mice eosinophilia was completely resolved after 5 weeks of OVA exposure. Despite this striking reduction in airway eosinophilia and AHR, Lck cre IL-4Ra 2/lox mice still presented with IL-5 and IL-13 cytokine-producing T cells in the lung. This would suggest that IL-4Ra expression on CD4 1 T cells contributes to chronic eosinophilia and AHR through factors other than chronic T H 2-type cytokine production, including IL-5 and IL-13. Chronic AHR can be sustained independently of IL-13 and might not correlate with the presence of T H 2 cytokine-producing T helper cells. 15, 46 We did not find significant differences in CD4 1 T cells producing either IFN-g or IL-10, cytokines associated with T H 1 or regulatory T-cell responses, respectively. However, IL-17-producing T-cell counts were constantly increased in CD4 1 T cell-specific IL-4Ra-deficient (Lck cre IL-4Ra 2/lox ) mice. IL-17 has been found to contribute to the development of allergic asthma but to downregulate established allergic airway inflammation and reduce pulmonary eosinophil recruitment and AHR in mouse models of OVA-induced asthma. 47 This might explain the reduced numbers of eosinophils in the presence of IL-5-producing CD4 1 T cells in Lck cre IL-4Ra 2/lox mice in which lung IL-17 levels were significantly increased.
In our study IL-17 neutralization in the acute phase of allergic airway disease did not significantly alter AHR development but reduced numbers of BAL neutrophils significantly. In the chronic phase AHR and airway eosinophilia was resolved faster in Lck cre IL-4Ra 2/lox mice in the presence of high numbers of IL-17-producing CD4 1 T cells. Therefore our study does not support an important role for IL-17 in the development of acute AHR, but we cannot rule out a protective rule of IL-17 during the chronic phase of the disease. On the other hand, T H 17 cells are upregulated in the lungs of asthmatic patients and linked to severe clinical phenotypes, such as neutrophilic steroid-resistant asthma, and are often considered to be detrimental in allergic airway disease. 29 We found a significant reduction in serum concentrations of total and OVA-specific IgE in Lck cre IL-4Ra 2/lox mice in the acute phase and during chronic allergen challenge. An acute allergic airway response can develop independently of IgE in mice, but mast cells and FcεRI contribute to the development of AHR in chronic asthma through antibody-mediated mechanisms. [48] [49] [50] Therefore it is possible that the reduced AHR in Lck cre IL-4Ra 2/lox mice is due to reduced IgE antibody titers affecting mast cell-mediated responses.
This study extends our understanding of the regulation of acute and chronic allergic airway responses and T H 2-type immune responses. We provide substantial evidence for differential requirements of IL-4Ra-responsive CD4 1 T cells during the acute and chronic phases of allergic airway disease. IL-4Ra expression on CD4 1 T cells plays a major role in the pathogenesis of chronic asthma and the regulation of allergen-specific T H 17 responses, whereas acute asthmatic pathology and T H 2 responses developed in the absence of IL-4Ra-responsive CD4 1 T cells and IL-4. The molecular mechanisms behind IL-4-independent T H 2 differentiation in response to OVA and AHR during chronic allergic airway responses remain to be determined.
METHODS
Analysis of in vitro cytokine production
For analysis of ex vivo cytokine production, single-cell suspensions from individual lungs of OVA-treated and control mice were incubated for 120 hours at 4 3 10 6 cells/mL in 200 mL of IMDM (Gibco, Loughborough, United Kingdom)/10% FCS (Delta, Johannesburg, South Africa) in 96-well plates. Cells were stimulated with OVA (100 mg/mL), and supernatants were collected after 120 hours. Concentrations of IL-5, IFN-g (BD Biosciences), and IL-17 (R&D Systems) were measured by using sandwich ELISA assays, according to the manufacturer's protocol. 
